Mad Hedge Biotech and Healthcare Letter January 15, 2026 Fiat Lux Featured Trade: (PROGRESS LIKE CLOCKWORK) (GILD), (RHHBY), (JNJ), (ACLX)
Tag Archives: (GILD)
Back in 2016, I told a hedge fund crowd in Tokyo that Gilead (GILD) was the biotech equivalent of a Seiko Spring Drive. Quietly brilliant, ruthlessly precise, engineered to perform for decades without needing applause. A few chuckled. Then Biktarvy happened. Now Yeztugo is here, and those same folks are calling me for dinner reservations […]
Mad Hedge Biotech and Healthcare Letter December 30, 2025 Fiat Lux Featured Trade: (BIOTECH’S WATERLOO: THE STOCKS THAT CONQUERED AND THE ONES THAT DIDN’T) (IDXX), (CAH), (HCA), (COR), (MCK), (GILD), (JNJ), (LLY), (ISRG), (WBA), (MRK), (BMY), (MRNA), (BIIB), (ILMN)
Napoleon once said, “In victory, you deserve champagne. In defeat, you need it.” Healthcare investors popped both in 2025. While the sector at large looked like a casualty of macro shrapnel, a few names marched through the battlefield with earnings like artillery fire – and stock prices to match. The top-line view was grim: the […]
Mad Hedge Biotech and Healthcare Letter October 21, 2025 Fiat Lux Featured Trade: (PATENT CLIFF DIVING) (GILD)
Three months ago, I was having dinner with a former FDA reviewer who spent 15 years evaluating HIV drugs. Between bites of overpriced salmon, he mentioned something that made me nearly choke on my wine. “The lenacapavir approval process,” he said casually, “was the smoothest I’ve seen in years. Usually there’s some bureaucratic drama, but […]
Mad Hedge Biotech and Healthcare Letter October 16, 2025 Fiat Lux Featured Trade: (THE LAZINESS PREMIUM) (GSK), (AZN), (ABBV), (PFE), (GILD)
I spent last Tuesday afternoon on a call with a fund manager who runs $3 billion and couldn’t explain to me why his team was avoiding GSK (GSK). Something about HIV competition and patent cliffs and the usual hand-waving you get from analysts who haven’t actually dug into the numbers. I let him finish his […]
Mad Hedge Biotech and Healthcare Letter October 2, 2025 Fiat Lux Featured Trade: (THE DIVIDEND KING THAT KEEPS GROWING ITS KINGDOM) (ABBV), (WBA), (AMGN), (GILD)
A Chicago lawyer named Russ Gremel walked into a brokerage in 1945 with $1,000 and a theory so simple it barely qualified as an investment thesis. He figured people would always need medicine and women would always buy makeup, so he bought shares in Walgreens (WBA) and promptly forgot about them. Seventy years later, when […]
- 1
- 2